S. Glück

S. Glück, F. Gorouhi, 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A woman's heart

S. Glück, M. Ewer, 2009, Cancer.

Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin.

S. Glück, 2005, The oncologist.

The expanding role of epirubicin in the treatment of breast cancer.

S. Glück, 2002, Cancer control : journal of the Moffitt Cancer Center.

The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer

S. Glück, 2001, Breast cancer.

Extending the clinical benefit of endocrine therapy for women with hormone receptor-positive metastatic breast cancer: differentiating mechanisms of action.

S. Glück, 2014, Clinical breast cancer.

Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.

M. Untch, G. von Minckwitz, S. Glück, 2013, Breast.

Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women

S. Glück, M. Kittaneh, 2011, Breast cancer : basic and clinical research.

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

G. Hortobagyi, R. Theriault, J. Simeone, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer.

L. Chow, Hyo S Han, M. Toi, 2011, European journal of cancer.

Exemestane as First-Line Therapy in Postmenopausal Women With Recurrent or Metastatic Breast Cancer

S. Glück, 2009, American journal of clinical oncology.

High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma

S. Glück, P. Forsyth, T. Cheng, 2003, Bone Marrow Transplantation.

Participation in Cancer Clinical Trials

M. Antoni, J. Hurley, S. Glück, 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

A Review of the Prevention of Invasive Breast Cancer with Raloxifene in Postmenopausal Women

S. Glück, E. Santos, A. Castrellon, 2009 .

Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.

S. Glück, A. Castrellon, 2009, American journal of therapeutics.

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer

L. Koniaris, M. Jordá, J. Slingerland, 2012, Breast Cancer Research and Treatment.

A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer

G. Lopes, S. Glück, A. Montero, 2012, Breast Cancer Research and Treatment.

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

A. Schneeweiss, N. Harbeck, J. Cortes, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas.

L. Tye, P. Goss, A. Stewart, 1999, Leukemia & lymphoma.

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

N. Harbeck, J. O’Shaughnessy, D. Yardley, 2015, Trials.

Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer.

S. Glück, T. Koru-Sengul, A. Montero, 2015, Clinical breast cancer.

Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis.

C. Russell, J. O’Shaughnessy, S. Glück, 2013, Breast.

HER2-positive metastatic breast cancer: a double-edged sword

S. Glück, R. Mahtani, J. Sandoval-Sus, 2012 .

Generation of dendritic cells: role of cytokines and potential clinical applications.

S. Glück, R. Syme, 2001, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

M. Coppes, S. Glück, P. Duggan, 2002, Bone Marrow Transplantation.

A Low CD34+ Cell Dose Predicts Relapse and Death Early following Autologous Blood Stem Cell Transplantation

S. Glück, J. Luider, J. Klassen, 2001, Hematology.

The CD3−16+56+ NK cell count independently predicts autologous blood stem cell mobilization

S. Glück, J. Luider, J. Klassen, 2001, Bone Marrow Transplantation.

Eribulin monotherapy in a patient with heavily pretreated metastatic breast cancer: Case study and review of the literature

S. Glück, F. Gorouhi, 2012 .

The Role of Taxanes in the Treatment

S. Glück, 2008 .

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

S. Glück, 2008 .

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

S. Glück, J. Cortés, A. Montero, 2012, Cancer treatment reviews.

The human adenoidal mast cell. Susceptibility to different secretagogues and secretion inhibitors.

S. Glück, G. Risse, W. Schmutzler, 1985, International archives of allergy and applied immunology.

A randomized trial of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (asct) compared to standard chemo therapy (ct) in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) clinical trials group study

J. Dancey, D. Tu, K. Pritchard, 2001 .

Acceleration of Telomere Loss by Chemotherapy Is Greater in Older Patients with Locally Advanced Head and Neck Cancer

K. Riabowol, S. Glück, D. Hao, 2006, Clinical Cancer Research.

Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer.

S. Okuno, S. Glück, S. Bayraktar, 2020, Future oncology.

Abstract P5-15-03: nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial

A. Schneeweiss, N. Harbeck, J. Cortes, 2017 .

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

N. Harbeck, J. O’Shaughnessy, D. Yardley, 2016, Trials.

Dendritic cell-based therapy: a review focusing on antigenic selection.

S. Glück, R. Syme, T. Bryan, 2001, Journal of hematotherapy & stem cell research.

Evaluation of three rapid RNA extraction reagents: relevance for use in RT-PCR's and measurement of low level gene expression in clinical samples.

S. Glück, M. Bewick, T. Chadderton, 1997, Cellular and molecular biology.

NOAH Study: Is It Really Setting the New Standard for Preoperative Systemic Therapy in HER2-Positive Early Breast Cancer?

S. Glück, 2009 .

Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation

S. Glück, J. Klassen, D. Stewart, 2000, Bone Marrow Transplantation.

Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT)

M. Rodriguez-Galvez, S. Glück, J. Luider, 2003, Bone Marrow Transplantation.

Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.

D. Brizel, W. Mendenhall, B. Murphy, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support

R. Lafrenie, S. Glück, M. Bewick, 1999, Bone Marrow Transplantation.

The use of photodynamic therapy in bone marrow purging.

A. Ho, S. Glück, C. Mulroney, 1994, Seminars in oncology.

Daily injections of the glutathione disulfide mimetic NOV-002 ameliorates hematologic toxicities from neoadjuvant chemotherapy in breast cancer patients enrolled in the NEO-NOVO trial, and significantly increases circulating dendritic cells.

E. Garrett-Mayer, S. Glück, Ying Zhu, 2009 .

Biologic Impact and Clinical Implication of mTOR Inhibition in Metastatic Breast Cancer

S. Glück, G. Westin, C. Perez, 2013, The International journal of biological markers.

A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer

G. Lopes, S. Glück, A. Montero, 2012, Breast Cancer Research and Treatment.

VBAMDex chemotherapy in advanced multiple myeloma *

I. Schedel, H. Deicher, K. Schumacher, 1988, European Journal of Haematology.

Bioassay for determination of cisplatin activity in serum and urine

S. Glück, S. Gangopadhyay, J. Wolff, 2004 .

Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer.

J. Lucci, S. Glück, N. Lambrou, 2009, The journal of supportive oncology.

Most often, patients presenting with neurological symptoms do not yet have a cancer diagnosis; therefore, detection of onconeuronal antibodies may help diagnosis. History and physical examination along with breast imaging should be performed in patients with

S. Glück, D. Hansra, 2014 .

Paraneoplastic neurological syndromes in breast cancer

S. Glück, D. Hansra, 2014 .

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657

S. Glück, S. Glück, 2013 .

Abstract P3-06-11: Response and long-term outcomes after neo-adjuvant chemotherapy: Pooled dataset of patients stratified by molecular subtyping using MammaPrint and BluePrint

J. Peeters, G. Somlo, S. Glück, 2012 .

Storage of blood for in vitro generation of dendritic cells.

S. Glück, P. Duggan, R. Syme, 2002, Cytotherapy.

Generation of dendritic cells ex vivo: differences in steady state versus mobilized blood from patients with breast cancer, with lymphoma, and from normal donors.

S. Glück, P. Duggan, D. Stewart, 2001, Journal of hematotherapy & stem cell research.

Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer.

A. Ho, S. Glück, C. Sinoff, 1993, Leukemia.

Nonsteroidal Anti-inflammatory Drug Induced Thrombotic Thrombocytopenic Purpura

Karlos Z. Oregel, S. Glück, J. Ramdial, 2013, Clinical medicine insights. Blood disorders.

Molecularly targeted therapies for metastatic triple-negative breast cancer

S. Glück, S. Bayraktar, 2013, Breast Cancer Research and Treatment.

Retrospective radiographic study of skeletal changes after long‐term etretinate therapy

S. Glück, G. Goerz, R. Jungblut, 1987, The British journal of dermatology.

The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity.

S. Glück, R Syme, M Bewick, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunosuppressive acidic protein in malignant diseases. Clinical relevance?

S. Glück, W. Köster, 1991, Cancer.

Requirement for Phospholipase C-γ1 Enzymatic Activity in Growth Factor-Induced Mitogenesis

Michael F. Moran, M. Moran, Lianfeng Zhang, 1998, Molecular and Cellular Biology.

Update on PARP inhibitor therapy for solid tumors

S. Glück, S. Bayraktar, H. Darling, 2019, Journal of Cancer Prevention & Current Research.

Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy

S. Glück, E. Ahn, Emilie Wang, 2012, Breast cancer : basic and clinical research.

A randomized controlled trial of cognitive-behavioral stress management in breast cancer: survival and recurrence at 11-year follow-up

C. Carver, M. Antoni, G. Ironson, 2015, Breast Cancer Research and Treatment.

Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer

S. Glück, 2017, Clinical breast cancer.

Systemic therapy options in BRCA mutation-associated breast cancer

S. Glück, S. Bayraktar, 2012, Breast Cancer Research and Treatment.

Ductal carcinoma in situ: how should we treat it?

B. Arun, S. Glück, S. Bayraktar, 2013 .

Immunotherapy in breast cancer

S. Okuno, S. Glück, S. Bayraktar, 2019, Journal of carcinogenesis.

The Selective Uptake of Benzoporphyrin Derivative Mono‐Acid Ring A Results in Differential Cell Kill of Multiple Myeloma Cells in vitro

A. Ho, S. Glück, A. Chadderton, 1996, Photochemistry and photobiology.

Using modern molecular markers to tailor breast cancer treatment: a new era for personalized medicine

S. Glück, A. Loaiza-Bonilla, 2012 .

Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer

C. Carver, M. Antoni, A. Díaz, 2016, Psychosomatic medicine.

TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab

C. Perou, S. Glück, M. Royce, 2012, Breast Cancer Research and Treatment.

Rational combinations in metastatic breast cancer: Bevacizumab with chemotherapy

S. Glück, 2010 .

Management of women with BRCA1/2 mutation-associated breast cancer

S. Glück, S. Bayraktar, 2012 .

nab-Paclitaxel for the treatment of aggressive metastatic breast cancer.

S. Glück, 2014, Clinical breast cancer.

Treating Breast Cancer in the 21st Century: Emerging Biological Therapies

Stefan Glück, S. Glück, A. Montero, 2013, Journal of Cancer.

Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?

C. Vogel, G. Lopes, S. Glück, 2012, Current Oncology Reports.

High-dose therapy in breast cancer: out of favor but not out of promise

S. Glück, D. Stewart, 2000, Bone Marrow Transplantation.

Predictive factors for long-term engraftment of autologous blood stem cells

S. Glück, J. Luider, J. Klassen, 2000, Bone Marrow Transplantation.

Effects of dapsone on passive Arthus reaction and chemotaxis and phagocytosis of polymorphonuclear leukocytes

T. Ruzicka, S. Glück, A. Bauer, 1981, Archives of Dermatological Research.

Ex vivo expansion of hematopoietic stem cells.

S. Glück, 1999, Journal of hematotherapy & stem cell research.

Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients

L. Difrancesco, S. Glück, R. Woodman, 2002, Bone Marrow Transplantation.

A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer.

S. Glück, P. Cano, T. Koski, 1998, European journal of cancer.

Chemoprevention of breast cancer

S. Glück, A. Castrellon, 2008, Expert review of anticancer therapy.

Novel Cytotoxic Agents in the Treatment of Metastatic Breast Cancer

S. Glück, A. Montero, S. Warsch, 2012, Current Breast Cancer Reports.

Management of capecitabine-related gastrointestinal toxicities in women with breast cancer

S. Glück, S. Bayraktar, 2011 .

Evaluation of sICAM-1, sVCAM-1, and sE-Selectin levels in patients with metastatic breast cancer receiving high-dose chemotherapy.

L. Zhang, R. Lafrenie, A. Parissenti, 2004, Stem cells and development.

Research Report Evaluation of sICAM-1, sVCAM-1, and sE-Selectin Levels in Patients with Metastatic Breast Cancer Receiving High-Dose Chemotherapy

L. Zhang, S. Glück, M. Bewick, 2004 .

Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?

S. Glück, A. Yip, Elizabeth Lam-Yan Ng, 2012, Expert opinion on therapeutic targets.

Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis

S. Glück, 2001 .

Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy

J. Peeters, G. Somlo, S. Glück, 2013, Breast Cancer Research and Treatment.

Adjuvant Therapy for Early Breast Cancer

S. Glück, M. Kittaneh, 2011 .

Comparison of CD34 and Monocyte‐Derived Dendritic Cells from Mobilized Peripheral Blood from Cancer Patients

S. Glück, R. Syme, L. Robertson, 2005, Stem cells.

Priming with dendritic cells can generate strong cytotoxic T cell responses to chronic myelogenous leukemia cells in vitro.

S. Glück, P. Duggan, R. Syme, 2004, Stem cells and development.

Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review

P. Bejarano, S. Glück, A. Montero, 2012, Journal of Medical Case Reports.

Primary ectopic breast cancer presenting as a vulvar mass.

M. Jordá, G. Lopes, S. Glück, 2006, Clinical breast cancer.

Prostate Cancer-Associated Trousseau´S Syndrome Versus Asymptomatic Isolated Muscular Calf Vein Thrombosis as the Origin of Acute Submassive Pulmonary Embolism: A Case Report and Review of the Literature

A. Giagounidis, S. Glück, A. Tsamaloukas, 2020 .

Macrophages as independent prognostic factors in small T1 breast cancers.

Consuelo Alvarez, C. Milikowski, M. Jordá, 2013, Oncology reports.

Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation.

L. Zhang, R. Lafrenie, A. Parissenti, 2001, Journal of hematotherapy & stem cell research.

Cutting Edge Communication Soluble Fas (CD95) Is a Prognostic Factor in Patients with Metastatic Breast Cancer Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplantation

L. Zhang, S. Glück, M. Bewick, 2001 .

Current results of a multicenter trial in multiple myeloma.

I. Schedel, H. Deicher, M. Gramatzki, 1986, Onkologie.

Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC).

A. Schneeweiss, S. Loibl, V. Nekljudova, 2018, Contemporary clinical trials.

Radiosensitivity of human clonogenic myeloma cells and normal bone marrow precursors: effect of different dose rates and fractionation.

J. Van Dyk, S. Glück, H. Messner, 1994, International journal of radiation oncology, biology, physics.

Soluble CD4, soluble CD8, soluble CD25, lymphopoieitic recovery, and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation.

A. Ho, A. Maghazachi, S. Glück, 1994, Blood.

Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.

J. D. Palma, H. Rugo, N. Harbeck, 2021, Clinical breast cancer.

Review Article Gene expression profiling in breast cancer

S. Glück, B. Arango, Celine L Rivera, 2013 .

Gene expression profiling in breast cancer

S. Glück, B. Arango, Celine L Rivera, 2013 .

Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials

S. Glück, J. Blum, N. Scotto, 2010, Breast Cancer Research and Treatment.

HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support

L. Zhang, A. Parissenti, S. Glück, 2001, Bone Marrow Transplantation.

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer

S. Glück, A. Loaiza-Bonilla, F. Socola, 2013, Clinical medicine insights. Women's health.

Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians

M. Penichet, M. Jordá, T. Ince, 2016, Breast Cancer Research and Treatment.

Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer Patient

C. Arteaga, S. Glück, C. K. Osborne, 2011, Clinical Cancer Research.

ER/HER2-Positive Metastatic Breast Cancer Patient Optimizing Chemotherapy-Free Survival for the

C. Arteaga, S. Glück, C. K. Osborne, 2011 .

Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review

S. Glück, A. Montero, C. Diaz-Montero, 2011, Expert review of clinical pharmacology.

Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?

K. Arheart, J. Net, S. Glück, 2014, Breast Cancer Research and Treatment.

Long‐term psychological benefits of cognitive‐behavioral stress management for women with breast cancer: 11‐year follow‐up of a randomized controlled trial

C. Carver, M. Antoni, B. Blomberg, 2015, Cancer.

Cutaneous histamine levels and histamine releasability from the skin in atopic dermatitis and hyper-IgE-syndrome

T. Ruzicka, S. Glück, 2004, Archives of Dermatological Research.

Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients

S. Glück, R. Syme, S. Gangopadhyay, 2004, Medical oncology.

Randomized controlled trial of cognitive behavioral stress management in breast cancer: a brief report of effects on 5-year depressive symptoms.

C. Carver, M. Antoni, B. Blomberg, 2015, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

Sleep Quality and Fatigue after a Stress Management Intervention for Women with Early-Stage Breast Cancer in Southern Florida

C. Carver, M. Antoni, M. Llabre, 2014, International Journal of Behavioral Medicine.

Bacterial decontamination of blood stem cell apheresis products

S. Glück, D. Guerin, K. Porter, 1998, Journal of clinical apheresis.

Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.

L. Goldstein, A. Ho, S. Glück, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose chemotherapy followed by autologous blood cell transplantation: a safe and effective outpatient approach

S. Glück, C. Sinoff, M. Dorreen, 1997, Bone Marrow Transplantation.

Neutropenic fever in patients after high-dose chemotherapy followed by autologous haematopoietic progenitor cell transplantation and human recombinant granulocyte-macrophage colony stimulating factor.

S. Glück, A. Gagnon, 1994, Bone marrow transplantation.

Brief cognitive-behavioral and relaxation training interventions for breast cancer: A randomized controlled trial.

C. Carver, M. Antoni, B. Blomberg, 2015, Journal of consulting and clinical psychology.

Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?

S. Glück, A. Castrellon, 2008, Clinical advances in hematology & oncology : H&O.

Improving outcomes in early-stage breast cancer.

S. Glück, T. Mamounas, 2010, Oncology.

Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis

F. Braiteh, S. Glück, R. Mahtani, 2018, Cancer management and research.